[go: up one dir, main page]

GB201709643D0 - Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues - Google Patents

Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues

Info

Publication number
GB201709643D0
GB201709643D0 GBGB1709643.9A GB201709643A GB201709643D0 GB 201709643 D0 GB201709643 D0 GB 201709643D0 GB 201709643 A GB201709643 A GB 201709643A GB 201709643 D0 GB201709643 D0 GB 201709643D0
Authority
GB
United Kingdom
Prior art keywords
glp
glucagon
analogues
peptide
administration
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
GBGB1709643.9A
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Zealand Pharma AS
Original Assignee
Zealand Pharma AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Zealand Pharma AS filed Critical Zealand Pharma AS
Priority to GBGB1709643.9A priority Critical patent/GB201709643D0/en
Publication of GB201709643D0 publication Critical patent/GB201709643D0/en
Priority to CN201880053014.6A priority patent/CN111032072A/en
Priority to PE2019002548A priority patent/PE20200678A1/en
Priority to DK21150552.4T priority patent/DK3881861T3/en
Priority to ES18734135T priority patent/ES2894629T3/en
Priority to EP24182737.7A priority patent/EP4424362A3/en
Priority to CA3066523A priority patent/CA3066523A1/en
Priority to BR112019026711-5A priority patent/BR112019026711A2/en
Priority to IL271245A priority patent/IL271245B2/en
Priority to AU2018285580A priority patent/AU2018285580B2/en
Priority to PCT/EP2018/065951 priority patent/WO2018229252A1/en
Priority to SG11201912161SA priority patent/SG11201912161SA/en
Priority to TW107120806A priority patent/TWI791539B/en
Priority to JP2020519850A priority patent/JP7200238B2/en
Priority to MX2019015054A priority patent/MX2019015054A/en
Priority to ARP180101685A priority patent/AR112109A1/en
Priority to RU2019142586A priority patent/RU2785662C9/en
Priority to CN202410762243.2A priority patent/CN118526577A/en
Priority to EP18734135.9A priority patent/EP3638291B1/en
Priority to EP21150552.4A priority patent/EP3881861B1/en
Priority to KR1020207001446A priority patent/KR102504200B1/en
Priority to DK18734135.9T priority patent/DK3638291T3/en
Priority to KR1020237006296A priority patent/KR102754148B1/en
Priority to ES21150552T priority patent/ES2989204T3/en
Priority to IL299864A priority patent/IL299864B2/en
Priority to US16/511,766 priority patent/US20200000883A1/en
Priority to CONC2019/0014028A priority patent/CO2019014028A2/en
Priority to ZA2019/08355A priority patent/ZA201908355B/en
Priority to CL2019003660A priority patent/CL2019003660A1/en
Priority to MX2023003828A priority patent/MX2023003828A/en
Priority to JP2022203265A priority patent/JP7566859B2/en
Priority to US18/496,636 priority patent/US12297251B1/en
Priority to ZA2024/02068A priority patent/ZA202402068B/en
Priority to AU2024202486A priority patent/AU2024202486B2/en
Priority to US18/956,370 priority patent/US20250136657A1/en
Ceased legal-status Critical Current

Links

GBGB1709643.9A 2017-06-16 2017-06-16 Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues Ceased GB201709643D0 (en)

Priority Applications (35)

Application Number Priority Date Filing Date Title
GBGB1709643.9A GB201709643D0 (en) 2017-06-16 2017-06-16 Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues
IL299864A IL299864B2 (en) 2017-06-16 2018-06-15 Dosing regimen for glucagon-like peptide (GLP-2) analog administration 2
RU2019142586A RU2785662C9 (en) 2017-06-16 2018-06-15 Dosing schemes for administration of glucagon-like peptide 2 (glp-2) analogues
CN202410762243.2A CN118526577A (en) 2017-06-16 2018-06-15 Dosage regimen for administration of glucagon-like peptide 2 (GLP-2) analogs
DK21150552.4T DK3881861T3 (en) 2017-06-16 2018-06-15 Dosage regimens for administration of glucagon-like peptide-2 (GLP-2) analogs
ES18734135T ES2894629T3 (en) 2017-06-16 2018-06-15 Dosage Guidelines for Administration of Glucagon-Like Peptide-2 (GLP-2) Analogues
EP24182737.7A EP4424362A3 (en) 2017-06-16 2018-06-15 Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
CA3066523A CA3066523A1 (en) 2017-06-16 2018-06-15 Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
BR112019026711-5A BR112019026711A2 (en) 2017-06-16 2018-06-15 dosage regimens for the administration of glucagon-2-like peptide analogs (glp-2)
IL271245A IL271245B2 (en) 2017-06-16 2018-06-15 Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
AU2018285580A AU2018285580B2 (en) 2017-06-16 2018-06-15 Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues
PCT/EP2018/065951 WO2018229252A1 (en) 2017-06-16 2018-06-15 Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
SG11201912161SA SG11201912161SA (en) 2017-06-16 2018-06-15 Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
TW107120806A TWI791539B (en) 2017-06-16 2018-06-15 Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
JP2020519850A JP7200238B2 (en) 2017-06-16 2018-06-15 Dosage regimen for administration of glucagon-like peptide 2 (GLP-2) analogs
MX2019015054A MX2019015054A (en) 2017-06-16 2018-06-15 Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues.
ARP180101685A AR112109A1 (en) 2017-06-16 2018-06-15 DOSAGE REGIMES FOR THE ADMINISTRATION OF GLUCAGON-PEPTIDE-2 (GLP-2) ANALOGUES
CN201880053014.6A CN111032072A (en) 2017-06-16 2018-06-15 Dosage regimen for administering glucagon-like peptide 2(GLP-2) analogs
EP18734135.9A EP3638291B1 (en) 2017-06-16 2018-06-15 Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
PE2019002548A PE20200678A1 (en) 2017-06-16 2018-06-15 DOSAGE FOR THE ADMINISTRATION OF GLUCAGON-2 TYPE PEPTIDE ANALOGS (GLP-2)
EP21150552.4A EP3881861B1 (en) 2017-06-16 2018-06-15 Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
KR1020207001446A KR102504200B1 (en) 2017-06-16 2018-06-15 Dosage regimen for administration of glucagon-like-peptide-2 (GLP-2) analogues
DK18734135.9T DK3638291T3 (en) 2017-06-16 2018-06-15 Dosage regimens for administration of glucagon-like peptide-2 (GLP-2) analogs
KR1020237006296A KR102754148B1 (en) 2017-06-16 2018-06-15 Dosage Regimes for the Administration of Glucagon-like-peptide-2 (GLP-2) Analogues
ES21150552T ES2989204T3 (en) 2017-06-16 2018-06-15 Dosage guidelines for administration of glucagon-like peptide-2 (GLP-2) analogues
US16/511,766 US20200000883A1 (en) 2017-06-16 2019-07-15 Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
CONC2019/0014028A CO2019014028A2 (en) 2017-06-16 2019-12-12 Dosage for the administration of glucagon-2-like peptide analogues (glp-2)
ZA2019/08355A ZA201908355B (en) 2017-06-16 2019-12-13 Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
CL2019003660A CL2019003660A1 (en) 2017-06-16 2019-12-13 Dosages for the administration of glucagon-2-like peptide analogs (glp-2).
MX2023003828A MX2023003828A (en) 2017-06-16 2019-12-13 Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues.
JP2022203265A JP7566859B2 (en) 2017-06-16 2022-12-20 Dosage regimen for administration of glucagon-like peptide 2 (GLP-2) analogues
US18/496,636 US12297251B1 (en) 2017-06-16 2023-10-27 Injection pen for subcutaneous administration of a peptide
ZA2024/02068A ZA202402068B (en) 2017-06-16 2024-03-13 Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
AU2024202486A AU2024202486B2 (en) 2017-06-16 2024-04-16 Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues
US18/956,370 US20250136657A1 (en) 2017-06-16 2024-11-22 Method for adjusting a parenteral support (ps) volume in a human subject

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
GBGB1709643.9A GB201709643D0 (en) 2017-06-16 2017-06-16 Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues

Publications (1)

Publication Number Publication Date
GB201709643D0 true GB201709643D0 (en) 2017-08-02

Family

ID=59462471

Family Applications (1)

Application Number Title Priority Date Filing Date
GBGB1709643.9A Ceased GB201709643D0 (en) 2017-06-16 2017-06-16 Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues

Country Status (2)

Country Link
AR (1) AR112109A1 (en)
GB (1) GB201709643D0 (en)

Also Published As

Publication number Publication date
AR112109A1 (en) 2019-09-18

Similar Documents

Publication Publication Date Title
SG11201912161SA (en) Dosage regimes for the administration of glucagon-like-peptide-2 (glp-2) analogues
IL268751A (en) Pharmaceutical compositions for combination therapy
GB201807942D0 (en) Pharmaceutical formulation
IL254772A0 (en) Pharmaceutical compositions for combination therapy
GB201701935D0 (en) Medicament delivery devices
IL267703B (en) Pharmaceutical compositions for combination therapy
IL271226A (en) Pharmaceutical formulation
PT3426294T (en) Pharmaceutical formulation
IL279127A (en) Delivery devices for administering drugs
IL278927A (en) Pharmaceutical formulation
EP3597235A4 (en) Medicinal liquid administering device
EP3263155A4 (en) Drug solution administering device
ZA202102871B (en) Pharmaceutical formulation
IL266537A (en) Pharmaceutical formulation
SG11202010124SA (en) Stable pharmaceutical formulation
SMT202300074T1 (en) Stable pharmaceutical composition for oral administration
ZA201807851B (en) Pharmaceutical formulation
PT3601277T (en) Pharmaceutical formulation
IL275144A (en) Pharmaceutical formulation
PT3650024T (en) Pharmaceutical composition for nasal administration
ZA201804588B (en) Pharmaceutical formulations for the treatment of diabetes
IL279128A (en) Delivery devices for administering drugs
GB201607794D0 (en) Medicament delivery devices
GB201709643D0 (en) Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues
GB201800873D0 (en) Dosage regimes for the administration of glucagon-like-peptide-2 (GLP-2) analogues

Legal Events

Date Code Title Description
AT Applications terminated before publication under section 16(1)